You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it. In addition as per local health authority Regulations, some of our products are not approved for sales, marketing or distribution in all countries.
NO
YES
BACK TO ALL NEWS/

29-04-2020

FY 2019 Results General Investor Call

Following the release of its Full Year 2019 results Kedrion S.p.A. is pleased to arrange a General Investor Call – (Credit Update)

Date & Time: Thursday 30 April 2020 @ 11.00 UKT / 12.00 CET

Dial-in:

ITALY +39 02 805 88 11
UK +44 1 212818003
FRANCE +33 170918703
GERMANY +49 69255114451
SPAIN +34 917699497

 

Speakers:
Simone Boaglio – Chief of Central Services
Peer Hansen – Global Chief Financial Officer
Pasquale Fraiese – Corporate Finance & Treasury

DOWNLOAD THE FY 2019 RESULTS PRESENTATION

For further information, please write to [email protected].


About Kedrion

Kedrion is a leading biopharmaceutical company that specializes in the development, production and distribution of plasma-derived therapeutic products for use in treating serious diseases, disorders and conditions such as immune system deficiencies and coagulation disorders. The Company operates through a fully integrated business model from the collection of plasma in its own centers in the United States and Hungary to fractionation and production in its manufacturing facilities located in Italy, Hungary and the United States. Headquartered in Castelvecchio Pascoli (Italy), Kedrion has over 2,700 employees and a commercial presence in approximately 100 countries worldwide. Kedrion places a high value on the welfare of those who benefit from its products, as well as on the people and the communities it serves. Additional information about Kedrion can be found at kedrion.com

For more information please contact: [email protected]